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3. Thesis abstract 
Background: Diabetes Mellitus is an emerging public health problem in Africa. 
Evidence suggests that globalization, rapid urbanization and a nutritional 
transition have led to the rise in the prevalence of diabetes mellitus in Africa. 
Diabetic retinopathy is a common complication of diabetes mellitus that causes 
visual impairment and subsequent blindness. Early detection and prompt 
treatment can prevent blindness in up to 90% of patients. The common risk 
factors for diabetic retinopathy include hypertension, hyperglycemia and long 
duration of diabetes. Other risk factors include obesity, hyperlipidemia, smoking, 
puberty and pregnancy. There is limited data on diabetic retinopathy and its 
associated risk factors in Zambia. An understanding of these factors would help 
in the effective management of diabetic retinopathy.  
 
Methods: A secondary data analysis of data obtained from a hospital-based 
cross-sectional study of diabetic patients attending diabetic clinics in the 
Copperbelt Province in Zambia was carried out. All diabetic patients that 
attended the retinopathy-screening program between April 2012 and September 
2012 were eligible for the primary study. The secondary data analysis was 
restricted to patients 18 years and older. Data analysis was carried out by R 
version 3.3.1. The characteristics of the study population were summarized using 
descriptive statistics. Univariate logistic regression analysis was used to select 
potential candidates for the multivariate regression model at p-value cutoff point 
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≤ 0.25 and variables of known clinical relevance were also included in the 
multivariable analysis. The final model fitness was checked using Hosmer and 
Lemeshow chi-square test. Finally, statistical significance was tested at P-value 
<0.05. 
 
Results: The prevalence of diabetic retinopathy was 19.4%. Multivariate analysis 
showed that the odds of diabetic retinopathy were significantly associated with 
age (OR =1.05: 95%Cl; 1.03-1.06), duration (OR=1.39: 95%Cl; 1.27-1.52), 
weight (OR =0.98: 95%Cl; 0.97-0.98), blood glucose (OR =1.04: 95Cl; 1.02-1.07) 
and systolic blood pressure (OR = 1.01: 95Cl; 1.00-1.02). 
 
Conclusion: Duration of diabetes, age, systolic blood pressure, weight and 
blood glucose levels were significantly associated with diabetic retinopathy in this 
study. More comprehensive population screening strategies and treatment 
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1.Purpose of the Study 
1.1 Study aim 




      1. To identify the risk factors of diabetic retinopathy in Zambia. 




Worldwide, diabetes mellitus affects four times more people today than it did 30 
years ago. (World Health Organization, 2016) Mathers and Loncar (2006) 
projected that by 2030 diabetes will be the seventh largest global cause of death 
worldwide. Diabetes and its complications have long been considered a problem 
of the industrialized countries. However, with the rising middle class and adoption 
of western lifestyle in Africa, the International Diabetes Foundation projects that 
the number of adults with diabetes mellitus in Africa will almost double by 2035 to 
reach 41·5 million. (Guariguata et al., 2014) This was supported by Boutayeb 
and Boutayeb (2005) who showed that non-communicable diseases are 
becoming more prevalent in Africa and adding to the disease burden that in the 
past were primarily caused by infectious diseases. A study done in Malawi 
showed that the prevalence of diabetes increased from less than 1.0% in the 
	 3	
1960s to 5.6% in 2009. (Msyamboza, Mvula & Kathyola, 2014) With the rise in 
diabetic cases it follows that there will be a rise in diabetic complications like 
diabetic retinopathy. 
A systematic review of diabetic retinopathy and maculopathy in Africa found a 
wide range of prevalence estimates for diabetic retinopathy that depended on 
whether the study was population-based or clinic-based. In population-based 
studies, the prevalence rates for diabetic retinopathy ranged from 30.2% to 
31.6%. In diabetic clinic-based studies, the reported prevalence rates for diabetic 
retinopathy ranged from 7.0% to 62.4%. (Burgess et al., 2013) A recent 
population based survey in Tanzania found the prevalence of diabetic retinopathy 
among diabetics to be 27.9%. (Cleland et al., 2016) The most common form of 
retinopathy was background diabetic retinopathy (19.1%), followed by 
maculopathy (16.1%), pre-proliferative (6%) and lastly proliferative diabetic 
retinopathy (2.9%). In comparison, the overall prevalence of diabetic retinopathy 
was higher in a population-based study in Kenya, which found the prevalence of 
diabetic retinopathy to be 35.9%. (Mathenge et al., 2014) However because of 
selection bias these studies cannot be generalized outside their context. A study 
in Ethiopia found that urban dwellers had a higher prevalence of diabetic 
retinopathy than rural dwellers. (Alemu et al., 2015) 
 
The World Health Organization has declared diabetic retinopathy  as the sixth 
leading cause of blindness, and as an important cause of avoidable blindness. 
(World Health Organization, 2016) Diabetic retinopathy is a microvascular 
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complication of both type 1 and type 2 diabetes mellitus and is an important 
cause of visual disability and blindness among diabetic patients. (Muaka & 
Longo-Mbenza, 2012). It is also the major cause of acquired vision loss in the 
economically productive age group worldwide. (Cheung & Wong, 2008) Diabetic 
retinopathy often has no early warning signs. However, early detection and 
treatment can prevent blindness in up to 70% of patients. (Mohamed, Gillies & 
Wong, 2007) Whereas diabetes in itself is a risk factor for vision loss there are 
other factors associated with diabetic retinopathy. 
 
Risk factors of diabetic retinopathy 
 
Kyari et al. (2014) demonstrated that diabetic patients in Nigeria are 3 times as 
likely to develop blindness as compared to the general population. A recent 
prospective cohort study done in Malawi, showed that the 2-year incidence of 
sight threatening diabetic retinopathy was 2.7% for diabetics who had no 
retinopathy, 27.3% for those with background retinopathy and 25% for those with 
pre-proliferative diabetic retinopathy. (Burgess et al., 2016)  
 
Duration of diabetes 
The Wisconsin Epidemiologic Study of Diabetic Retinopathy was an extensive 
study that followed people living with diabetes for 25 years in Wisconsin USA. It 
concluded that chances of having diabetic retinopathy increases with diabetes 
duration. It found that 67-98% of patients had diabetic retinopathy after 20 years.  
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(Klein et al., 2008) The study found that more than 80% of those with insulin 
dependent diabetes mellitus (type 1 diabetes) and more than 60% of non-insulin 
dependent diabetes mellitus (type 2 diabetes) would develop some degree of 
retinopathy after a 20-year history of diabetes. (Klein et al., 2008) However, a 
study in Kenya found that diabetic retinopathy occurs in younger diabetic patients 
compared to Western countries where diabetic retinopathy is associated with 
older diabetic patients. This was attributed to inadequate control of diabetes and 
hypertension in resource -poor nations. (Mathenge et al., 2014) 
 
Glycemic control 
Poor glycemic control of diabetes is associated with diabetic retinopathy. (Yau et 
al., 2012) Two large clinical trials found a relationship between glycemic control 
and the progression of diabetic retinopathy in both type 1 diabetes  
 (Diabetes Control and Complications Trial Research group [DCCT], 1993) and 
type 2 diabetes.  (UK Prospective Diabetes Study Group [UKPDS], 1998). The 
DCCT Research group found that intensive treatment in insulin-dependent 
diabetics reduced the incidence of diabetic retinopathy by 76% and the 
progression of diabetic retinopathy by 54%. The UKPDS showed that intensive 
treatment of diabetes reduced the development of any diabetic retinopathy by 
25% in the intensive treatment group compared with the conventional treatment 
group. In the Wisconsin Epidemiologic Study of Diabetic Retinopathy lower 
glycosylated hemoglobin was one of the factors found to be associated with 
improvement in diabetic retinopathy during the first four years of follow up. After 
	 6	
the 25 year follow up period it was demonstrated that people diagnosed most 
recently with a similar duration of diabetes had a lower prevalence of proliferative 
diabetic retinopathy independently of glycosylated hemoglobin level, blood 
pressure level, and presence of proteinuria. This was thought to be due to 
improvement in diabetes care over the study period. (Klein et al., 2008) 
 
Hypertension 
Blood pressure is an important risk factor for diabetic retinopathy. (Van Leiden et 
al., 2002) The UKPDS clinical trial demonstrated that hypertension is a risk factor 
for diabetic retinopathy in type 2 diabetes. Tight blood pressure control resulted 
in a 34% lower risk of progression of diabetic retinopathy in the study. (UK 
Prospective Diabetes Study Group, 1998) Hypertension very often coexists with 
diabetes. The incidence of hypertension is 3 times greater in people with Type 2 
diabetes when compared to those without diabetes.  (Rajalakshmi, Prathiba & 
Mohan, 2016) Hypertension is also a risk factor in type 1 diabetes. A prospective 
study showed that higher blood pressure is correlated to the early development 
of retinopathy in adolescents with type 1 diabetes, independent of other known 
risk factors. Both systolic and diastolic blood pressures contributed to the risk of 
retinopathy. (Gallego et al., 2008) In contrast, two large clinical trials the 
ACCORD study group (Buse et al., 2007) and the ADVANCE collaborative group 
(Patel et al., 2007) showed that intensive blood-pressure control did not reduce 




The role of lipids in the pathogenesis of diabetic retinopathy is still disputed. The 
Early Treatment of Diabetic Retinopathy Study data showed that lowering lipid 
levels decreased the risk of hard exudate formation and associated vision loss in 
patients with diabetic retinopathy. (Chew et al., 1996)Findings in the Wisconsin 
Epidemiologic Study of Diabetic Retinopathy study agreed with this, when an 
association was found between higher total serum cholesterol and retinal hard 
exudates in insulin-dependent persons. (Moss, Klein & Klein, 1999) In the 
Fenofibrate Intervention and Event Lowering in Diabetes Study (FIELD Study 
Investigators, 2005), among patients with type 2 diabetes, those treated with 
fenofibrate were less likely than controls to need laser treatment therefore had 
less severe retinopathy (5.2% vs 3.6%) Fenofibrate is used to treat 
high cholesterol and high triglyceride levels. However, there was no association 
found between total cholesterol and high density lipoproteincholesterol (HDL-
cholesterol) with diabetic retinopathy or with hard exudates in the older onset age 
group not using insulin.(Klein et al., 1991) The ADVANCE study  followed a 
cohort of 11140 patients with type 2 diabetes and concluded that HDL cholesterol 
is not an independent risk factor for development of diabetic retinopathy. (Morton 
et al 2012) 
 
3 Study Rationale  
Whilst a lot of research has been done on diabetic retinopathy in industrialized 
countries this is not the case in Africa, more so in Zambia. Zambia has a 
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population of 17.2 million. The International Diabetes Federation estimates the 
prevalence of diabetes to be 4.2% in Zambia. Therefore, there are approximately 
722 400 people living with diabetes in Zambia. There is limited information on 
diabetic retinopathy in Zambia. Evidence suggests that with the growing middle 
class in Zambia, and adoption of a western lifestyle, diabetes cases are 
becoming more prevalent with increasing household socio-economic position 
(Bailey et al., 2016) This study aims at providing an understanding of the risk 
factors of diabetic retinopathy in Zambia, which will aid in developing effective 
diabetic retinopathy management programs. The study findings will also lay a 
foundation for advocacy, aimed at expanding screening programs for early 




   4.1 Study design 
This study will be a secondary data analysis of data obtained from a hospital- 
based cross sectional study, which was investigating the general awareness and 
prevalence of diabetic retinopathy among diabetic patients attending diabetic 
clinics in the Copperbelt Province in Zambia.  
 
   4.2 Study setting  
The primary study was conducted in the Copperbelt Province of Zambia. The 
province has a total population of about 2,362,000. The major economic activity 
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in the Copperbelt is mining. Kitwe runs a new diabetic retinopathy screening 
programme that provides free screening for all diabetic patients in the province.  
Although the screening is restricted to Copperbelt Province, Kitwe Central 
hospital also receives referrals from across the country. 
 
      4.2.1 Inclusion criteria  
All diabetic patients that attended the retinopathy screening centres between 
April 2012 and September 2012 were eligible for the primary study. The 
secondary data analysis will be restricted to patients 18 years and older.   
 
     4.2.2 Exclusion criteria 
Diabetic patients who did not consent to be part of the study and those who did 
not attend the diabetic screening programme where excluded from the primary 
study.  
 
  4.3. Data collection  
In the primary study, pre-coded interviewer-administered questionnaires were 
used to obtain information from the diabetic patients. Retinal images were 
reviewed by the researcher to determine the prevalence of diabetic retinopathy. 
Records from the screening programme were compiled and matched to records 
of referrals at Kitwe Central Hospital. Data for this secondary analysis will be 
taken from the interviewer –administered questionnaires and records from the 
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screening programme. (Appendices A and B). Variables that are used in this 
analysis are listed in Table A-1. 
Table A-1: List of variables to be used for this secondary data analysis 
 




Duration of diabetes 
Blood glucose 
Systolic blood pressure 
Diastolic blood pressure 
BMI 
Intraocular pressure 
Seen by eye specialist 













5. Data analysis  
Statistical analysis will be carried out using R version 3.3.1. The characteristics of 
the study population will be summarized using descriptive statistics. Continuous 
variables will be described using means with standard deviations or medians with 
interquartile ranges depending on the data distribution, whilst categorical 
variables will be described using absolute numbers and percentages. 
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Analysis will include the use of Rank-sum and Kruskal–Wallis tests for 
continuous variables and chi-squared and Fischer tests for categorical variables. 
This will be done to determine if there are significant differences between 
different groups. Correlation between variables will be investigated and evaluated 
by use of scatter plots and frequency tables. 
 
    5.1 Model building 
The primary outcome variable which is diabetic retinopathy will be treated as a 
binary variable; presence of any form of diabetic retinopathy versus absence of 
diabetic retinopathy. A logistic regression model will be used to identify predictors 
of diabetic retinopathy with variables being included if they are known to be risk 
factors for diabetic retinopathy as shown by existing literature or if a statistically 
significant association was found during univariate analysis. The odds of having 
diabetic retinopathy will be reported with 95% confidence intervals (Cl) and a P-
value of <0.05 will be considered to indicate statistical significance.  
 
6. Potential Risks and Discomfort 
There will not be any direct involvement with participants in this study as it is a 
secondary data analysis and therefore it presents minimal risk to participants. 
  
7. Potential Benefits  
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The knowledge obtained from the study will provide further understanding of the 
risk factors of diabetic retinopathy in Zambia, which will aid in developing 
effective diabetic retinopathy management programs. The study findings will also 
lay a foundation for advocacy, aimed at expanding screening programs for early 
detection and treatment of diabetic retinopathy and its associated risk factors 
across Zambia. 
 
8. Ethical considerations 
Ethical approval for the primary study was obtained from relevant local ethical 
committees in the Copperbelt Province.  
 
 8.1 Informed consent  
There will be no direct contact with the study participants therefore informed 
consent will not be obtained. The primary study obtained consent from the 
patients.  
 
8.2 Privacy and confidentiality  
Electronic data will be used in the study. The primary study removed all patient 
identifiers and replaced them with a unique code. This study does not have 
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1.Introduction and objectives of this literature review 
Diabetes is on the rise globally. The number of adults living with diabetes has 
increased worldwide from an estimated 108 million in 1980 to 422 million in 2014. 
(World Health Organization, 2016) It is projected that by 2030 diabetes will be the 
seventh largest global cause of death worldwide. (Mathers & Loncar, 2006) Low 
and middle-income countries have seen a disproportionate increase in diabetes 
cases compared to high-income countries. (World Health Organization, 2016) 
The prevalence of diabetes in Africa increased from 3·1% in 1980 to 7·1% in 
2014, which is a 129·0% increase. (Allen, 2017) Globalization, rapid urbanization 
and changing food environments are the driving influences that have led to an 
increase in the risk and prevalence of diabetes and other non-communicable 
diseases (NCDs) in Africa. (Shaw, Sicree & Zimmet, 2010)  
 
At present, poor health systems in Africa struggle to cope with infectious 
diseases and now face the added burden of an increasing prevalence of NCDs 
like diabetes. The health systems in African countries are unable to manage the 
current burden of diabetes and its complications. Apart from lack of equipment 
and drugs for treatment, health care providers were found to have insufficient 
knowledge on managing diabetes and its complications. (Atun et al., 2017)  
 
The rise in diabetic cases inevitably means there will also be a rise in diabetic 
complications like diabetic retinopathy. Diabetic retinopathy has been declared 
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as the sixth leading cause of blindness, and as an important cause of avoidable 
blindness. (World Health Organization, 2016) Diabetic retinopathy (DR) is the 
leading cause of blindness among working-aged adults globally. (Kobrin Klein, 
2007) Diabetic retinopathy is a microvascular complication of both type 1 and 
type 2 diabetes and is an important cause of visual disability and blindness 
among diabetic patients. (Muaka & Longo-Mbenza, 2012) Diabetic retinopathy 
often has no early warning signs. However, early detection and treatment can 
prevent blindness in up to 70% of patients. (Mohamed, Gillies & Wong, 2007)   
 
This dissertation investigates the risk factors of diabetic retinopathy among a 
sample of diabetic patients in Zambia. It further quantifies the association of the 
risk factors to diabetic retinopathy. To inform this research, the objectives of the 
literature review are 
• To describe the natural history of diabetic retinopathy. 
• To provide an overview of the prevalence of diabetic retinopathy.  
• To describe the progression of diabetic retinopathy. 
• To describe existing evidence on factors associated with diabetic 
retinopathy. 
 
2. Search methods 
Pubmed, and Google Scholar were the search engines used to locate literature 
for this review. The search was restricted to English language publications, with 
no restriction applied with reference to time period or study design. Titles and 
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abstracts of resulting articles were reviewed and references of included studies 
and existing reviews were searched. 
Publications available through August 2017 were included in this review. Search 
strategies using MESH terms and free language are listed in box 1. 
 
Publications were included if: 
• The study population had either type 1 or type 2 diabetes 
• The study participants had risk factors for diabetic retinopathy 
• The outcome of interest was diabetic retinopathy 
 
Box 1: Search strategy 
 
Diabetes: Diabetic retinopathy, Proliferative diabetic retinopathy, diabetes mellitus 
 
Epidemiology: Prevalence, incidence, occurrence, epidemiology 
 
Risk: factors, risk factors 
 








3. Summary of Literature Review 
 
 3.1 Natural history of diabetic retinopathy 
Diabetic retinopathy is divided into two main forms: nonproliferative and 
proliferative. The early stages of diabetic retinopathy are mild nonproliferative 
abnormalities, which are characterized by increased vascular permeability. The 
disease then progresses to moderate and severe nonproliferative diabetic 
retinopathy (NPDR), which is characterized by vascular closure. It further 
progresses to proliferative diabetic retinopathy (PDR), which is characterized by 
neovascularization on the retina and posterior surface of the vitreous. Macular 
edema is the thickening of the retina from leaky blood vessels. It can develop at 
all stages of retinopathy and if present it can be further classified as mild, 
moderate and severe. (Fong et al., 2004);(Klein et al., 1984)  
 
 3.2 Overall prevalence of diabetic retinopathy 
A meta-analysis summarizing 35 studies carried out between 1980 - 2008 
analyzed data from over 22000 people with diabetes. The study estimated a 
prevalence of any diabetic retinopathy of 34.6% and of vision-threatening 
diabetic retinopathy of 10.2% within the diabetes population. (Yau et al., 2012) 
However since data was pooled from various sources this could provide many 
potential sources of heterogeneity that could influence accuracy of the estimates. 
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Due to the wide range of methods used in determining diabetes status in different 
studies an overestimation of diabetes prevalence rates could have resulted. 
 
It was estimated that in 2010 out of 32.4 million blind and 191 million visually 
impaired people, 0.8 million were blind and 3.7 million were visually impaired 
because of diabetic retinopathy. This represented a 27% increase in number of 
blind people and a 64% increase in the number of visually impaired people due 
to diabetic retinopathy compared to 1990 global estimates. Age-standardized 
prevalence of diabetic retinopathy-related blindness and visual impairment was 
found to be higher in Africa and South Asia. (Leasher et al., 2016)  
 
A systematic review of diabetic retinopathy and maculopathy in Africa found a 
wide range of prevalence estimates for diabetic retinopathy that depended on 
whether the study was population-based or clinic-based. In population-based 
studies, the prevalence estimates for diabetic retinopathy among people with 
diabetes was found to be between 30.2% and 31.6%. In diabetes clinic-based 
surveys, the prevalence estimates for diabetic retinopathy ranged from 7.0 to 
62.4%. (Burgess et al., 2013) However, the studies varied substantially in 
classification of retinopathy and methods used to ascertain the diagnosis. There 
is a paucity of population-based studies in Africa as large epidemiological studies 
are expensive. The majority of studies on diabetic retinopathy were hospital 
based. In hospital-based studies selection bias is a major issue and therefore 




3.3 Sight-threatening diabetic retinopathy 
A cross-sectional study in Malawi found the prevalence of sight threatening 
diabetic retinopathy to be 19.7% (14.7-24.6%) among type 2 diabetic patients 
and 18.8% (5.2-32.2%) among type 1 diabetic patients. (Glover et al., 2012) This 
is in contrast to a study conducted in the U.K that found a prevalence of sight 
threatening diabetic retinopathy in type 2 diabetic patients to be much lower at 
6.0%. However, the prevalence of sight-threatening diabetic retinopathy in type 1 
diabetic patients was 16.4% which is similar to the prevalence found in Malawi. 
The differences could be due to different methods in assessing diabetic 
retinopathy and variation in skills and knowledge to diagnose diabetic 
retinopathy. (Younis et al., 2002)  
 
   3.4 Progression 
A systematic literature review and meta-analysis of prospective studies carried 
out between1975 - 2008 assessed the rates of progression of diabetic 
retinopathy to proliferative diabetic retinopathy (PDR) and/or severe visual loss 
(SVL). The study showed that the overall incidence of PDR and SVL observed in 
studies after 1985 (2.6% for PDR and 3.2% for SVL at 4 years) were 
considerably lower than rates observed before 1985 (19.5% for PDR and 9.7% 
for SVL at 4 years). (Wong et al., 2009) This meta-analysis was carried out with 
studies from developed countries and shows that there is a decline in incidence 
of blindness due to diabetic retinopathy in developed countries attributed to 
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improvement in the management of diabetes. (Sabanayagam et al., 2016) 
However, the rates of progression of diabetic retinopathy in Africa are different. 
A recent 5-year cohort study in Malawi found the overall progression of diabetic 
retinopathy to be 48.4% for diabetic patients who did not have evidence of 
retinopathy at baseline. (Burgess et al., 2017) The study found the progression to 
sight-threatening diabetic retinopathy (STDR) for those with no diabetic 
retinopathy was 19.4%, which was 5 times higher in comparison to recent 
European studies which found estimates of progression to STDR from no 
diabetic retinopathy to be between 3.9% - 4.0% (Younis et al., 2003a; Younis et 
al., 2003b).  Burgess et al., 2017 found the 5-year incidence of STDR for those 
with background retinopathy to be 81.3%, which is 3 times higher than European 
estimates of between 26.8%- 28.9%. (Younis et al., 2003a; Younis et al., 2003b) 
 
 3.5 Risk Factors  
There are several risk factors for diabetic retinopathy. Longer duration of 
diabetes, poorer glycemic and blood pressure control are the main risk factors to 
be strongly associated with diabetic retinopathy. (Yau et al., 2012) Risk factors 
for diabetic retinopathy can be classified as modifiable and non-modifiable. The 
major modifiable risk factors are hyperglycemia, hypertension, obesity and 
hyperlipidemia. The non-modifiable risk factors include duration of diabetes, 
puberty and pregnancy. (Ting, Cheung & Wong, 2016) 
 
3.5.1 Modifiable risk factors: 
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Hyperglycemia  
Poor glycemic control of diabetes is associated with diabetic retinopathy. (Yau et 
al., 2012) Two large clinical trials found a relationship between glycemic control 
and the progression of diabetic retinopathy in both type 1 diabetes (Diabetes 
Control and Complications Trial (DCCT) Research Group, 1993) and type 2 
diabetes (UK Prospective Diabetes Study (UKPDS) Group, 1998). In type 1 
diabetes the DCCT Research group found that intensive therapy reduced the 
mean risk of developing diabetic retinopathy by 76% compared with conventional 
therapy. The study also found that intensive therapy slowed the progression of 
diabetic retinopathy by 54% and reduced the development of proliferative 
diabetic retinopathy or severe non-proliferative diabetic retinopathy by 47%. In 
type 2 diabetes the UKPDS showed that intensive treatment of diabetes reduced 
the development of any diabetic retinopathy by 25% in the intensive treatment 
group compared with the conventional treatment group. Davis (1998) supported 
this view that the effect of better glycemic control is important in preventing 
diabetic retinopathy and added that this extends across all ages, both diabetes 
types and all stages of retinopathy. 
In the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) lower 
glycosylated hemoglobin was one of the factors found to be associated with 
improvement in diabetic retinopathy during the first four years of follow up. After 
the 25 year follow up period it was demonstrated that more recently diagnosed 
cohorts with a similar duration of diabetes had a lower prevalence of proliferative 
diabetic retinopathy independently of glycosylated hemoglobin level, blood 
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pressure level, and presence of proteinuria. This was thought to be due to 
improvement in diabetes care over the study period. (Klein et al., 2008)  
Hypertension 
Blood pressure is an important risk factor for diabetic retinopathy. (Van Leiden et 
al., 2002) Controlling hypertension has been shown to reduce the risk of 
developing diabetic retinopathy and slowing its progression. (UK Prospective 
Diabetes Study (UKPDS) Group, 1998) A prospective study showed that higher 
blood pressure is correlated to the early development of retinopathy in 
adolescents with type 1 diabetes, independent of other known risk factors. Both 
systolic and diastolic blood pressures contributed to the risk of retinopathy. 
(Gallego et al., 2008) In contrast, two large clinical trials showed that the effect of 
intensive blood-pressure control are smaller than initially anticipated in reducing 
macrovascular and microvascular complications of diabetes. (Buse & ACCORD 
Study Group, 2007); (Patel & ADVANCE Collaborative Group, 2007)  
Hyperlipidemia  
The role of lipids in the pathogenesis of diabetic retinopathy is still disputed. The 
Early Treatment of Diabetic Retinopathy Study data showed that lowering lipid 
levels decreased the risk of hard exudate formation and associated vision loss in 
patients with diabetic retinopathy. (Chew et al., 1996) Findings in the Wisconsin 
Epidemiologic Study of Diabetic Retinopathy study agreed with this, when an 
association was found between higher total serum cholesterol and retinal hard 
exudates in insulin-dependent persons. (Moss, Klein & Klein, 1999) In the 
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Fenofibrate Intervention and Event Lowering in Diabetes Study, patients with 
type 2 diabetes treated with fenofibrate were less likely than controls to need 
laser treatment. They therefore had less severe retinopathy although the 
mechanism for this was not related to plasma lipid concentrations. (FIELD Study 
Investigators, 2005) Fenofibrate is used to treat high cholesterol and high 
triglyceride levels. However, there was no association found between total 
cholesterol and high-density lipoprotein cholesterol (HDL-cholesterol) with 
diabetic retinopathy or with hard exudates in the older onset age group not using 
insulin. (Klein et al., 1991) The ADVANCE study followed a cohort of 11140 
patients with type 2 diabetes and concluded that HDL cholesterol is not an 
independent risk factor for development of diabetic retinopathy. (Morton et al., 
2012)  
Obesity 
There are conflicting results on the association of diabetic retinopathy and a high 
Body Mass Index (BMI). (Ting, Cheung & Wong, 2016) In the WESDR being 
underweight (BMI < 20kg/m2) was associated with a high risk of severe diabetic 
retinopathy. (Klein, Klein & Moss, 1997; Klein et al., 1984) However, the Diabetes 
Incidence Study in Sweden found high BMI to be significantly associated with 
diabetic retinopathy. (Henricsson et al., 2003) Significant associations between 
high BMI and diabetic retinopathy were similarly reported in the DCCT and the 
WHO study. (Zhang et al., 2001) (Keen et al., 2001)  
Smoking 
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There is controversy on the role smoking has on diabetic retinopathy. The largest 
population-based study on diabetic retinopathy found no relationship between 
smoking status and progression of diabetic retinopathy. (Klein et al., 1998) 
However, Mhlhauser (1996) found a significant association between smoking and 
retinopathy although the strength of the relationship varied depending on the 
statistical model used. 
Non-modifiable risk factors: 
 Duration 
The Wisconsin Epidemiologic Study of Diabetic Retinopathy  was an extensive 
population-based study that followed people living with diabetes for 25 years in 
Wisconsin USA. Participants were divided into 3 groups.  
Group 1: participants with insulin dependent diabetes mellitus (IDDM) when age 
at diagnosis was 30 or more. 
Group 2: participants with insulin dependent diabetes mellitus (IDDM) when age 
at diagnosis was less than 30. 
Group 3: participants with non-insulin dependent diabetes mellitus when age at 
diagnosis was less than 30 years. 
The groups showed the following prevalence: 
Group 1: The prevalence of diabetic retinopathy was 28.8% in participants who 
had diabetes for less than five years whilst it was 77.8% in participants who had 
diabetes for 15 years or more. Proliferative diabetic retinopathy was found in 
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2.0% of participants who had diabetes for less than five years and 15.5% of 
participants who had diabetes for 15 or more years. 
Group 2: The prevalence of diabetic retinopathy was 17% in participants who had 
diabetes for less than five years whilst it was 97.5% in participants who had 
diabetes for 15 years more. Proliferative diabetic retinopathy was found in 1.2% 
of participants who had diabetes for less than ten years and in 67% of 
participants who had diabetes for 35 or more years. 
Group 3: The prevalence of diabetic retinopathy among those with non-insulin 
dependent diabetes mellitus was 36% at diagnosis whilst proliferative retinopathy 
was present in 5% after 20 years of diabetes. 
The importance of duration as a risk factor for the development of diabetic 
retinopathy has been confirmed in several other studies. (Yau et al., 2012);(Ding 
& Wong, 2012)  
Puberty and Pregnancy 
The stage of sexual development is associated with diabetic retinopathy. (Klein, 
Moss & Klein, 1990) Olsen et al. (2004) demonstrated this when they found that 
type 1 diabetic patients diagnosed after puberty experienced a shorter mean time 
to develop diabetic retinopathy than those diagnosed before puberty. Pregnancy 
was reported to be associated with progression of diabetic retinopathy. (Klein, 
Moss & Klein, 1990) However, Stalnikiewicz et al. (2010) showed that 
progression of diabetic retinopathy is low particularly if diabetic retinopathy was 
mild or absent at the beginning of the pregnancy. 
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4. Identification of gaps or needs for further research 
Although there have been numerous epidemiological studies in high-income 
countries since the early 1980’s, on the prevalence, incidence and risk factors of 
diabetic retinopathy, there are very few high-quality studies on the prevalence of 
diabetic retinopathy in Africa. (Klein et al., 1984; Yau et al., 2012) Differences in 
population characteristics warrant the importance of conducting high-quality local 
studies in Africa. 
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Purpose: Diabetic retinopathy is an important cause of avoidable blindness. The 
factors associated with diabetic retinopathy among diabetic patients at Kitwe 
Central Hospital in Zambia were identified and assessed. 
Methods: This was a secondary data analysis of data obtained from a hospital-
based cross-sectional study of diabetic patients attending diabetic clinics in the 
Copperbelt Province in Zambia. All diabetic patients that attended the 
retinopathy-screening centres between April 2012 and September 2012 were 
eligible for the primary study. The secondary data analysis was restricted to 
patients 18 years and older. Data analysis was carried out by R version 3.3.1. 
The characteristics of the study population were summarized using descriptive 
statistics. Univariate logistic regression analysis was done to select potential 
candidates for the multivariate regression model at p-value cutoff point ≤ 0.25 
and variables of known clinical relevance were also included in the multivariable 
analysis. The final model fitness was checked using Hosmer and Lemeshow chi- 
square test. Finally, statistical significance was tested at p-value <0.05. 
Results:  The prevalence of diabetic retinopathy was 19.4%.  Multivariate 
analysis showed that the odds of diabetic retinopathy were significantly 
associated with age (OR =1.05:95%Cl; 1.03-1.06), duration (OR=1.39:95%Cl; 
1.27-1.52, weight (OR =0.98:95%Cl; 0.97-0.98,blood glucose (OR =1.04:95Cl; 
1.02-1.07), systolic blood pressure (OR = 1.01:95Cl; 1.00-1.02) 
Conclusion: This study highlighted the statistical significance of the duration of 
diabetes as well as some important modifiable risk factors for diabetic retinopathy 
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among a sample of diabetic patients in Zambia, such as weight, blood glucose 
and systolic blood pressure. More comprehensive population screening 
























Diabetes mellitus is on the increase globally but low and middle-income countries 
have seen a disproportionate rise in diabetes mellitus cases compared to high-
income countries.  The rise in diabetes mellitus cases has been attributed to the 
increasing incidence and prevalence of type 2 diabetes mellitus. Population 
growth, aging populations and urbanization with its associated changing lifestyles 
(reduced physical activity and increased obesity) have led to increases in type 2 
diabetes mellitus.1 It is projected that the number of adults with diabetes mellitus 
in Africa will almost double by 2035 to reach 41·5 million. 2  
Diabetic retinopathy is the most common microvascular complication of both type 
1 and type 2 diabetes mellitus. The prevalence of diabetic retinopathy is closely 
associated with the upsurge in prevalence of diabetes mellitus and is the leading 
cause of blindness among the productive age group globally.3, 4 In 2015, among 
the 216·6 million people found to have moderate or severe vision impairment 
globally, 2.6 million had diabetic retinopathy and it was projected that the number 
would increase to 3.2 million people by 2020.5   
Most patients who develop diabetic retinopathy have no symptoms until the very 
late stages when it is too late for effective treatment.6 However, early detection 
and treatment can prevent blindness in up to 70% of patients.7 Screening and 
follow-up is crucial for the effective management of diabetic retinopathy. 
However, follow-up rates are often poor in Africa due to various reasons 
including the cost to patients, poor transportation and lack of knowledge of 
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services.8 The high rates of undiagnosed diabetes mellitus show that existing 
screening practices are not effective.9 Additional strategies like targeting 
modifiable risk factors are therefore necessary in curbing the incidence of 
diabetic retinopathy. Several observational and randomized studies have shown 
that optimal blood glucose and blood pressure control are essential intervention 
strategies for the prevention of diabetic retinopathy and for slowing its 
progression. 4  
In contrast to the large amount of research that has been done on diabetic 
retinopathy in industrialized countries, there is limited research on diabetic 
retinopathy in Africa and more so in Zambia. Given the paucity of data on 
diabetic retinopathy in Zambia this study examines its risk factors to provide a 
better understanding of the factors associated with the disease, which can in turn 
aid in developing effective prevention programs. 
 
Methods 
This study is a secondary data analysis of a hospital-based cross-sectional study 
that aimed to determine the prevalence of diabetic retinopathy among diabetic 
patients attending diabetic clinics in the Copperbelt province of Zambia as well as 
the factors associated with treatment compliance in that population. The province 
has a total population of about 2,362,000. 
 Every diabetic patient that attended the retinopathy-screening program between 
April 2012 and September 2012 was eligible for the primary study. Diabetic 
retinopathy was classified as background retinopathy, pre-proliferative or 
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proliferative diabetic retinopathy. This was based on retinal images that were 
examined by a grader. This secondary data analysis classifies diabetic 
retinopathy as present or absent. The analysis was restricted to patients 18 years 
and older. Patients who had bilateral cataract were excluded from the study. 
 
Data collection         
Data for this analysis came from a review of records from the diabetic retinopathy 
screening program and interviewer-administered questionnaires, which were 
used to obtain information from the diabetic patients in the primary study (see 
Appendix A and B). The data was entered into Microsoft excel. 
 
Data analysis 
Data was analyzed using R version 3.3.1. Descriptive statistics were used to 
summarise the characteristics of the study population. Categorical variables were 
described using frequencies and percentages whilst continuous variables were 
described using means with standard deviations. The primary outcome variable 
was diabetic retinopathy and was treated as a binary variable; presence of any 
form of diabetic retinopathy versus absence of diabetic retinopathy. 
Univariate logistic regression analysis was carried out to investigate the 
unadjusted association between variables and the outcome. It was also used to 
identify potential predictors for the full model with cutoff point of P-value ≤ 0.25 . 
The variable smoking had over 50% of its values missing and was therefore not 
included in the model. 
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Multivariable logistic regression analysis was done to estimate the effect of the 
predictors on diabetic retinopathy. The model was built by purposeful selection of 
variables and compared by the likelihood ratio test.  Interactions and confounders 
were checked by using change in beta coefficient with cutoff point beta change 
greater than 20%. The final model fitness was checked using Hosmer and 
Lemeshow chi- square test. Finally, statistical significance was tested at p-value 
<0.05. 
 
Ethical considerations  
This study was conducted after getting ethical approval from University of Cape 
Town Human Research Ethics Committee. The TDRC Ethics Review committee 
in Zambia had approved the primary study. There was no direct contact with the 
study participants therefore informed consent was not obtained. The primary 
study obtained consent from the patients. The study adheres to the guidelines of 
the Declaration of Helsinki.  
 
Results 
Socio demographic characteristics 
Overall 2401 diabetic patients were included in this study. Of these, 2220 
(92.5%) were between the ages of 40-79 years. The mean age for the diabetic 
patients was 55.8 years. The age range was between 18 and 92 years. The age 
category with the largest number of diabetic retinopathy cases was among the 
40-59 years old - 261 (56.1%) followed by the 60-79 years old - 189 (40.6%). The 
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mean age for study participants with diabetic retinopathy was 57.2 years whilst 
the mean age for those who did not have diabetic retinopathy was 55.4 years. 
Among the males 261 (19.7%) had diabetic retinopathy, whilst 204 (18.9%) 
females had diabetic retinopathy. Kitwe had the highest proportion 141 (30.3%), 
of diabetic patients with diabetic retinopathy followed by Ndola with 119 (25.6%). 
Masaiti had the lowest number of patients with diabetic retinopathy 7 (1.5%). 
Among the 2401 diabetic patients, 1148 (47.8%) had a family history of diabetes 
and among those with a family history of diabetes 253 (22%) had diabetic 
retinopathy. (Table C-1) 
 
Clinical and bio chemical characteristics of study subjects 
The prevalence of diabetic retinopathy among study participants was 465 
(19.4%). Three hundred and fifty (14.6%) had background diabetic retinopathy, 
53 (2.2%) had pre-proliferative retinopathy and 62 (2.6%) had proliferative 
retinopathy. Of the diabetic patients with diabetic retinopathy 163 (35.1%) had 
type 2 diabetes mellitus while 58 (12.5%) had type 1 diabetes mellitus and 244 
(52.5%) had unknown status. Among patients with diabetic retinopathy, 130 
(28%) had lived with diabetes mellitus for 11- 15 years. Three hundred and 
sixteen (68%) of the diabetic patients with diabetic retinopathy used oral 
hypoglycemic agents, 108 (23.2%) used insulin, 27 (5.8%) used diet and 14 
(3%)reported no treatment. Three hundred and eight (66.2%) diabetic retinopathy 
patients had a systolic blood pressure greater than 140mmhg and 244 (54.8%) 
had a diastolic blood pressure greater than 90mmhg.Two hundred and seven 
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(49.6%) of the diabetic patients with diabetic retinopathy had blood glucose 
levels above 11mmol/l. Pertaining to the Body Mass Index of patients with 
diabetic retinopathy, 165 (35.6%) were of normal weight, 169 (36.4%) were 
overweight, 103 (22.2%) were obese and 27 (5.8%) were underweight. The 
mean Body Mass Index for diabetic patients with diabetic retinopathy was 26.6 
whilst the mean Body Mass Index for those who did not have retinopathy was 
28.1. Seventeen (3.7%) of diabetic patients with diabetic retinopathy had a 
history of smoking whilst 71 (3.6%) of diabetic patients without diabetic 
retinopathy had a history of smoking. (Table C-1) 
 
Table C-1: Demographic and clinical characteristics of study participants 





































































































Univariate logistic regression analysis showed that except for diastolic pressure, districts 
and the sex of the patient other predictors satisfied the p-value criteria of ≤0.25 and were 
potential candidates for the multivariable logistic regression analysis. (Table C-2) 
 
Multivariate logistic regression revealed that age, duration, systolic blood pressure, 
weight and blood glucose were associated to diabetic retinopathy. (Table C-2) 
 
When adjusted for duration of diabetes, systolic blood pressure, weight, blood glucose 
levels, type of treatment, family history of diabetes and type of diabetes, the odds of 
having diabetic retinopathy increased by 5% for each year increase in age (OR: 1.05; 
95% CI: 1.03-1.06). When adjusted for systolic blood pressure, weight, age, blood 
glucose levels, family history type of diabetes and type of treatment, the odds of having 
diabetic retinopathy increase by 39% for each year increase in duration of diabetes. 
(OR: 1.39; 95% CI: 1.27-1.52). The odds of having diabetic retinopathy reduced by 2% 
for each increase in weight when adjusted for age, duration of diabetes, systolic blood 
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pressure, treatment type, family history, blood glucose and type of diabetes. When 
adjusted for age, duration of diabetes, systolic blood pressure, weight, type of treatment, 
family history of diabetes and type of diabetes, the odds of having diabetic retinopathy 
increased by 4% for each unit increase in random blood glucose level. The interaction 
between age and duration was statistically significant. 
 
Table C-2: Logistic regression analysis for factors associated with diabetic retinopathy 
	
	 Univariate	analysis	 	 Multivariate	analysis	 	
Potential	risk	factors	 OR	 (95%	CL)	 p-value	 OR	 (95%CL)	 p-value	
	 	 	 	 	 	 	
Age	 1.02	 (1.01-1.03)	 		0.001*	 1.05	 (1.03-1.06)	 <0.001	
	 	 	 	 	 	 	
Duration	 1.11	 (1.09-1.11)	 <0.001*	 1.39	 (1.27-1.52)	 <0.001	
	 	 	 	 	 	 	
Systolic		 1.01	 (1.01-1.02)	 <0.001*	 1.01	 (1.00-1.02)	 <0.001	
	 	 	 	 	 	 	
Diastolic	 1.02	 (1.01-1.02)	 <0.001*	 			1.00	 (0.99-1.01)	 		0.382	
	 	 	 	 	 	 	
Weight	 0.98	 (0.97-0.99)	 <0.001*	 0.98	 (0.97-0.98)	 <0.001	
	 	 	 	 	 	 	
Height	 0.99	 (0.99-1.00)	 		0.248	 			Not	included	 	
	 	 	 	 	 	 	
BMI	 0.94	 (0.93-0.97)	 <0.001*	 			Not	included	 	
	 	 	 	 	 	 	
District	 	 	 	 			Not	included	 	
Kitwe	 0.87	 (0.57-1.34)	 	0.507	 	 	 	
Konkola	 			1.10	 (0.66-1.86)	 	0.719	 	 	 	
Luanshya	 1.19	 (0.74-1.93)	 	0.485	 	 	 	
Masaiti	 2.22	 (1.10-4.46)	 	0.025	 	 	 	
Mufulira	 0.86	 (0.54-1.38)	 	0.516	 	 	 	
Nchanga	 0.93	 (0.59-1.50)	 	0.772	 	 	 	
Ndola	 1.18	 (0.78-1.83)	 	0.439	 	 	 	
	 	 	 	 	 	 	
Gender	 	 	 	 	 	 	
Male																																 				ref	 	 	 	 	 	
Female	 0.99	 (0.83-1.19)	 0.951	 0.9	 (0.74-1.10)	 0.298	
	 	 	 	 	 	 	
Treatment	type	 	 	 	 	 	 	
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Nothing	 				ref	 	 	 	 	 										ref	
Diet	 0.98	 (0.58-1.67)	 0.929	 0.92	 (0.51-1.65)	 0.773	
Oral	 1.25	 (0.82-1.97)	 0.319	 1.02	 (0.64-1.69)	 0.924	
Insulin	 2.08	 (1.32-3.37)	 0.002	 1.39	 (0.81-2.45)	 0.241	
	 	 	 	 	 	 	
family	history	 	 	 	 	 	 	
No	 				ref	 	 	 	 	 									ref	
Yes	 1.16	 (0.96-1.40)	 0.123	 1.06	 	(0.86-1.31)	 							0.562	
Don’t	know	 1	 (0.75-1.33)	 0.995	 0.92	 	(0.67-1.25)	 							0.603	
	 	 	 	 	 	 	
Blood	glucose	 1.04	 1.02-1.06	 0.001*	 1.04	 1.02-1.07	 <0.001	
	 	 	 	 	 	 	
Diabetes	type	 	 	 	 	 	 	
Type	1	 ref	 	 	 	 	 ref	
Type	2	 0.53	 0.40-0.72	 0.001*	 0.7	 0.47-1.05	 0.083	
Not	specified	 500	 0.37-0.67	 0.001*	 0.63	 0.43-0.91	 0.013*	
	 	 	 	 	 	 	
duration:age	 	 	 	 0.99	 0.99-1	 <0.001	






Diabetic retinopathy is an emerging public health problem in low and middle-
income countries due to the rise of diabetes mellitus.10 In this study, the 
prevalence of any diabetic retinopathy was 19.4%. This was comparable to the 
prevalence estimates of 20.5% found in a study that looked at diabetic patients 
over the age of 18 years in Egypt.11 However, this study used slit lamp 
biomicroscopy to diagnose diabetic retinopathy. A systematic review of diabetic 
retinopathy and maculopathy in Africa reported the overall prevalence rates of 
diabetic retinopathy in diabetic clinic-based studies to be between 7.0% and 
62.4%. 12 Only 9 out of 62 studies on diabetic retinopathy in Africa used retinal 
	 15	
photographs and 6 of the studies were conducted in South Africa. 12 A clinic-
based study in Tanzania that used digital fundal images to diagnose diabetic 
retinopathy reported a prevalence estimate of 27.9%. 13 Variations in the quality 
of the health care system could account for the differences in the prevalence 
estimates. These studies however cannot be generalized outside their context 
due to selection bias. 
Diabetic retinopathy is the main cause of acquired vision loss in the economically 
productive age group in developed countries.14 This study revealed that diabetic 
retinopathy similarly affects the economically productive age group in Zambia. 
This therefore underscores the importance of understanding factors associated 
with diabetic retinopathy for its effective management.  
Duration of diabetes was the risk factor that was most strongly associated with 
diabetic retinopathy in this study. The odds ratio for duration of diabetes 
increased significantly from the univariate to multivariate analysis. (Table C-2) 
The proportion of patients with diabetic retinopathy increased with increased 
duration of diabetes. These findings support previous studies that showed that 
the prevalence of diabetic retinopathy increases with duration of disease. 15,16 
However, developing diabetes mellitus in low and middle-income countries 
causes a great financial burden on the family and the outcome is often poor with 
reduced life expectancy.9 This was demonstrated in this study by the smaller 
percentage of patients with diabetic mellitus who had the longest duration of 
diabetes. This can be attributed to the competing risk of death. Age was found to 
be significantly associated with diabetic retinopathy. The effect of age on diabetic 
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retinopathy interacts with the effect brought about by duration of diabetes 
mellitus. Therefore, the older a diabetic patient is, the longer they have lived with 
diabetes mellitus and the more likely they are to have diabetic retinopathy. 
The study did not find any statistically significant association between the gender 
of patients and diabetic retinopathy. This finding is comparable to other studies 
that did not find a statistically significant difference in the prevalence of diabetic 
retinopathy among males and females.14  
The study findings suggested that more patients with diabetic retinopathy had 
type 2 diabetes mellitus than type 1 diabetes mellitus. In low-income countries, 
type 1 diabetes mellitus is associated with a low life expectancy due to poor 
health care, socioeconomic conditions and unavailability of medication.17 
Therefore patients with type 1 diabetes mellitus may not survive long enough to 
develop complications like diabetic retinopathy. 
The association between systolic blood pressure and diabetic retinopathy was 
statistically significant in this study. The odds of having diabetic retinopathy 
increased by 1 % for every unit increase in systolic blood pressure, when 
adjusted for other variables. This is consistent with studies done in America that 
found a 10% excess risk of diabetic retinopathy for each 10mmhg increase in 
systolic blood pressure. 15 
This study found that random blood glucose levels were positively associated 
with diabetic retinopathy. For every unit increase in blood glucose the odds of 
having diabetic retinopathy increased by 4 %. This is consistent with intervention 
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studies that found that improved glycemic control delayed the onset and 
progression of diabetic retinopathy. 18,19 
Several studies have yielded inconclusive results on the association of obesity 
with diabetic retinopathy. In one study diabetic patients who were underweight 
were found to have an increased risk of developing diabetic retinopathy 20 whilst 
another study 21 demonstrated an association between a larger Body Mass Index 
and diabetic retinopathy. In this study there was a 2% reduction in the odds of 
getting diabetic retinopathy per kilogram increase in weight. The reason for this 
could be that in resource-limited environments, those with low weight may be 
more likely to be poor, have a concomitant disease and ultimately be more at risk 
to have a poor health outcomes. 9,22,23 The association of family history of 
diabetes mellitus and diabetic retinopathy was not statistically significant in this 
study. 
There was a wide range of diabetic retinopathy prevalence by location among the 
study cohort (30% prevalence in Kitwe compared to 1.5% in Masaiti). The 
differences can be attributed to the larger size of the population in bigger cities 
like Kitwe or Ndola, which contributed more study patients compared to small 
towns like Masaiti. 
The strengths of this study are the large sample size of diabetic patients and the 
fact that it was carried out in a healthcare setting with access to existing records. 
An additional strength was the study design, which made it possible to analyze 
the outcome and various risk factors. 
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A limitation in this study was selection bias. Since the Copperbelt Province is one 
of the most developed provinces in Zambia, it is not representative of the 
Zambian population and therefore the results of this study cannot be generalized. 
Random blood sugar, which is a less sensitive marker, was used as a measure 
for blood glucose control rather than glycosylated hemoglobin (HbA1c.) With the 
available data it was not possible to ascertain the duration of diabetes as 
opposed to the time since diagnosis or the diabetic retinopathy prevalence when 
only a small portion of diabetic patients attend clinical services and fewer see an 




In this study, duration of diabetes was strongly associated diabetic retinopathy on 
multivariate logistic regression. Targeting individuals with a longer duration of 
diabetes would therefore be an important strategy in the prevention and 
management of diabetic retinopathy. Other risk factors associated with diabetic 
retinopathy were age, systolic blood pressure, weight and blood glucose levels. 
This suggests that modifiable risk factors of diabetic retinopathy in the Zambian 
population are largely similar to those found in developed countries. Controlling 
these risk factors may reduce both the prevalence and impact of diabetic 
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APPENDIX A : Demographic and Diabetic History Questionnaire 
 
Knowledge, practice, and awareness regarding diabetic retinopathy among 










# Question Responses Coding 
Demographic questions 
1 Patient identification number 
 
  
2 Age (in years)   
3 Sex Male  (1) 
Female  (2) 
 
4 Education Primary I  (1) 
Seceondary II  (2) 
Tertiary III   (3) 
 
5 Marital status Married  (1) 
Single  (2) 
Divorced  (3) 
Widowed  (4) 
 
6 Religion Christian  (1) 
Hindu  (2) 
Muslim  (3) 
Other  (4) 
 




8 How long have you been coming to this diabetic 
clinic? (months) 
  
9 When was your diabetes first diagnosed? 
(number of months ago) 
  
10 What were the first symptoms that alerted you or 
your doctor that you had diabetes? 
Frequent urine  (1) 
Large water intake  (2) 
Visual loss  (3) 
Diabetic foot  (4) 
Diabetic coma  (5) 
Dry mouth  (7) 
Others  (6) 
 
 
11 Who made the initial diagnosis of diabetes?  Doctor  (1) 
Nurse  (2) 





12 Where was the first diagnosis done? Tertiary Center  (1) 
Secondary level   (2) 
Primary level  (3) 
District Hospital  (4) 
(Health center)  (5) 
(Health post)  (6) 
  Others (7) 
 
 
Current understanding of eye disease due to diabetes 
13 What are the major consequences or disabilities 
that a person with diabetes can get? (tick all) 
            Diabetic foot    (1)         
               Amputation   (2)    
                Visual loss   (3) 
                       Stroke   (4) 
           Heart disease   (5) 
         Kidney disease   (6) 
                     Others  (7) 
 
 
14 Do you have any of these consequences or 
disabilities right now? (tick all) 
             Diabetic foot   (1) 
               Amputation   (2) 
                Visual loss   (3) 
                       Stroke   (4) 
           Heart disease   (5) 
       Kidney disease   (6) 
Others (7) 
 
15 Have you been provided any education on how to 
prevent disabilities due to diabetes? 
Yes  (1) 
No  (2) 
 
16 If yes, did the education include information on 
eye disease? (if Q15 = No, leave blank) 
Yes  (1) 
No  (2) 
 
17 Who provided the information on eye disease? (if 
Q15 = No, leave blank.  Also, if Q16 = No, leave 
blank) 
Doctor  (1) 
Nurse  (2) 
Other health work  (3) 
Others (4) 
 
18 Can eye disease due to diabetes be treated? Yes  (1) 
No  (2) 
I don`t Know (3) 
 
19 Have you ever had an eye examination to detect if 
you have any eye problems due to diabetes?  
Yes  (1) 
No  (2) 
 
20 If yes, where did you have the eye examination? If 
Q19 = No, leave blank 
Kitwe CH  (1) 
Ndola GH  (2) 
Company hospital (3) 
Other hospital  (4) 
Health centre  (5) 
 
21 When should a diabetic patient see an eye doctor  On diagnosis   (1) 
When referred   (2) 
After visual loss   (3) 
Others    (4) 
 
22 How frequently should a person with diabetes 
have an eye exam? 
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APPENDIX B: EYE EXAMINATION FORM 
	
DILATED EYE SCREENING 
ID Number:……………………………………….	 Mobile Number: 
………………………………………….	
Name of Patient:………………………………………………… 
……………………………………………………………………..	
Age                                  Sex: Male   	Female	 	
From screening form :   Date: …………………….                                Presenting Visual Acuity: 
Blood pressure:                   Fasting Blood sugar:                     R/E                            L/E 
Digital Fundus photograph taken:  Y  N                             
Lens Opacity  R/E: No   Lens opacity interfering with photograph Yes    Referred to Kitwe Eye Dept    
  L/E: No   Lens opacity interfering with photograph Yes     
Diabetic Retinopathy  R/E:  R 0 = No DR      M0 = No Mac    
    R1 = BDR      `` MNR= Mac not referable    
    R2 = Pre=proliferative DR     M1 = referable maculopathy    
    R3 = Proliferative DR    
    P = Photocoagulation    OL/UG = other lesion/ungradable     
   L/E:       R 0 = No DR      M0 = No Mac    
    R1 = BDR       MNR= Mac not referable    
    R2 = Pre=proliferative DR     M1 = referable maculopathy    
    R3 = Proliferative DR     
















	 Referral to Kitwe 
Eye Dept for 
further 
assessment: 
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